Showing 761-770 of 1805 results for "".
Redefining Treatment Success and Patient Preference in PsO
https://practicaldermatology.com/topics/psoriasis/redefining-treatment-success-and-patient-preference-in-pso/60991/We are seeing a growing emphasis on patient-centered care and long-term disease control.Physician Spotlight: Candrice R. Heath, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-candrice-r-heath-md/23766/Word of Mouth: Which Review Sites Carry the Most Weight?
https://practicaldermatology.com/youngmd-connect/resident-resource-center/word-of-mouth-which-review-sites-carry-the-most-weight/20396/Pearls for Choosing and Initiating Psoriasis Therapy
https://practicaldermatology.com/topics/psoriasis/PD0309_18-php/22872/Members of the psoriasis panel at the 2009 South Beach Symposium last month offered insights on patient care.A Practical Approach to Disorders of Hypopigmentation
https://practicaldermatology.com/topics/pigmentary-disorders/a-practical-approach-to-disorders-of-hypopigmentation/67254/Hypopigmentation comprises a broad spectrum of disorders characterized by decreased pigmentation in the presence of intact but functionally impaired melanocytes.DermWireTV: Derm Salaries Down, Allergan Eyes Soliton, Emsculpt Week
https://practicaldermatology.com/topics/practice-management/dermwiretv-derm-salaries-down-allergan-eyes-soliton-emsculpt-week/19941/Just under half of all physicians in the US are employed in physician-owned medical practices, new data from the American Medical Association show. Medscape’s annual Physician Compensation Report reveals that physicians overall saw a reduction in income due to the COVID-19 pandemic; income for dermDermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)Look to the EAST: Shared Decision Making in the Era of New Therapies
https://practicaldermatology.com/topics/atopic-dermatitis/look-to-the-east-shared-decision-making-in-the-era-of-new-therapies/23372/Assessing Efficacy, Accessibility, Safety, and Tolerability is the key to a meaningful dialogue with patients.New Products and Devices
https://practicaldermatology.com/columns/new-products/new-products-and-devices/20567/New products and pharmacologic developmentsAssessing Dystrophic Nails: Finding the Cause
https://practicaldermatology.com/topics/general-topics/assessing-dystrophic-nails-finding-the-cause/21397/A podiatrist offers a unique perspective on the causes of dystrophic toenails.